Performance measurements from the first phase of our ongoing two-part validation study for the Prostate Core Mitomic Test™ for prostate cancer yield positive results.
Our tissue-based Mitomic Prostate Core Test™ receives positive results from an independent post-market study conducted by the prestigious uro-oncology trials management organization, CUSP Group.
The study will evaluate the Company’s novel mitochondrial DNA-based test for accurately identifying prostate cancer in blood samples from men with elevated PSA levels that are at risk for prostate cancer.
MDNA Life Sciences acquires Mitomic Technology and product pipeline.
Dr. Steinfels will oversee the imminent acquisition of the intellectual property and assets of Mitomics Inc., including the tissue-based Prostate Core Mitomic Test™, as well as the proprietary Mitomic Technology™ platform.